Satellos Bioscience (MSCL) Q2 2026 earnings summary

Executive summary

• Reported six-month interim data from TRAILHEAD Phase 2 adult DMD study showing reduced muscle fat fraction, increased total effort, stable strength, and improved quality of life.

• SAT-3247 granted FDA Fast Track Designation for Duchenne muscular dystrophy (DMD).

• BASECAMP Phase 2 pediatric DMD study actively enrolling, with clinical data expected in Q4 2026.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $61.8 million as of June 30, 2026, up from $27.7 million at year-end 2025, mainly due to an equity offering.

• R&D expenses rose to $9.6 million for Q2 2026 from $4.4 million in Q2 2025, reflecting increased clinical trial and manufacturing costs.

• G&A expenses increased to $2.5 million for Q2 2026 from $1.9 million in Q2 2025, driven by higher headcount, professional fees, and Nasdaq listing costs.

• Net loss for Q2 2026 was $11.7 million ($0.56 per share), compared to $5.6 million ($0.39 per share) in Q2 2025.

Outlook and guidance

• Clinical data from BASECAMP pediatric trial expected in Q4 2026.

• Plans to submit IND for SAT-3247 in facioscapulohumeral muscular dystrophy (FSHD) and launch a Phase 2 trial in the second half of 2026.

• Current cash position expected to fund operations through 2027.